# Clinical trials recruiting in Oregon: 1,217 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 1,217 trials recruiting or not yet recruiting with a site in Oregon, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Oregon: 1,217 rows for $60.85, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 19 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/state/oregon

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 1,217
- Recruiting or not yet: 1,217
- Read on: November 19, 2026

## Trials

The 25 newest of 1,217, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07947082 | An Adaptive Parent-mediated Intervention to Improve Outcomes for Autistic Children | Florida International University | Not applicable | Not yet recruiting | Autism | 680 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947082) |
| November 16, 2026 | NCT07938294 | Sotatercept in the Treatment of Methamphetamine-Associated Pulmonary Arterial Hypertension | Oregon Health and Science University | Phase 4 | Not yet recruiting | Pulmonary Arterial Hypertension (PAH), Methamphetamine Use Disorder | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938294) |
| November 12, 2026 | NCT07930559 | Effect of S-Ibuprofen Gel on Pain in Acute Soft Tissue Contusions | Aponia Laboratories, Inc. | Phase 3 | Recruiting | Acute Pain Due to Trauma | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930559) |
| November 6, 2026 | NCT07923045 | A Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of MR-146 in Subjects With Stage I and Stage II Neurotrophic Keratopathy | Viatris Inc. | Phase 1/2 | Recruiting | Neurotrophic Keratopathy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923045) |
| October 29, 2026 | NCT07904793 | Care COMPASS Study | Fitbit LLC | Not applicable | Not yet recruiting | Diabetes Mellitus ( Type 1 and Type 2), Hypertension | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904793) |
| October 28, 2026 | NCT07902401 | Bone Stress Injury Recovery and Return to Sport: A Natural History Study | HealthPartners Institute | Observational | Recruiting | Bone Stress Fracture | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902401) |
| October 28, 2026 | NCT07901751 | Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT) | Ray Therapeutics, Inc. | Phase 2/3 | Recruiting | Retinitis Pigmentosa (RP), Inherited Retinal Diseases | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901751) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 23, 2026 | NCT07892326 | Inflammatory Pathways Modulated by Prenatal Mindfulness: A Route to Improve Maternal Child Emotional Well Being and Whole Person Health | Oregon Health and Science University | Not applicable | Not yet recruiting | Inflammation, Depression Disorder, Mindfulness, Emotional Well-being, Physical Health, Mental Health | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892326) |
| October 15, 2026 | NCT07876219 | Dynamic, Real-world Learning, Innovative Mobility, and Versatile Exploration (DRIVE): Evaluating a Dose-matched Developmental Powered... | University of Washington | Not applicable | Not yet recruiting | Cerebral Palsy | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876219) |
| October 13, 2026 | NCT07871214 | A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage... | Bristol-Myers Squibb | Phase 2 | Not yet recruiting | Early-Stage Non-Small Cell Lung Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871214) |
| October 9, 2026 | NCT07868939 | Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) | Viking Therapeutics, Inc. | Phase 3 | Recruiting | Weight Loss | 560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868939) |
| October 9, 2026 | NCT07868835 | Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) | Viking Therapeutics, Inc. | Phase 3 | Recruiting | Weight Loss | 560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868835) |
| October 9, 2026 | NCT07868419 | Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets | Trevi Therapeutics | Phase 3 | Recruiting | Idiopathic Pulmonary Fibrosis | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868419) |
| October 9, 2026 | NCT07867080 | A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME). | 4D Molecular Therapeutics | Phase 3 | Recruiting | Diabetic Macular Edema (DME) | 514 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867080) |
| October 5, 2026 | NCT07858266 | Deployment of a Novel National Institute of Neurological Disorders and Stroke Clinical, Biomarker, Imaging, and Modifiers (CBI-M)... | University of Michigan | Observational | Recruiting | Traumatic Brain Injury | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858266) |
| October 5, 2026 | NCT07857655 | Intraoperative Methadone for the Management of Postoperative Pain in Patients With Head and Neck Cancers | OHSU Knight Cancer Institute | Phase 4 | Recruiting | Head and Neck Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Carcinoma | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857655) |
| October 5, 2026 | NCT07857200 | The Use of Risk Prediction to Identify Patients at Risk for Chronic Kidney Disease: Patient and Provider Interventions for Patients at High... | Kaiser Permanente | Not applicable | Recruiting | CKD - Chronic Kidney Disease | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857200) |
| September 30, 2026 | NCT07850063 | ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and... | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850063) |
| September 30, 2026 | NCT07849231 | A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms | Damora Therapeutics | Phase 1 | Recruiting | Myeloproliferative Neoplasms (MPNs) | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07849231) |
| September 28, 2026 | NCT07844694 | Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder | OHSU Knight Cancer Institute | Phase 1 | Recruiting | Familial Platelet Disorder With Associated Myeloid Malignancy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844694) |
| September 22, 2026 | NCT07833917 | RISE Lab: Building Resilience Through Responsibility | University of Oregon | Not applicable | Recruiting | Mental Health | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833917) |
| September 18, 2026 | NCT07829107 | The PIONEER Comparative Effectiveness Study - Project 2 | University of Michigan | Not applicable | Recruiting | Head Injury Trauma, Traumatic Brain Injury, Mild | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829107) |
| September 18, 2026 | NCT07828613 | Accelerated Flap Coverage Versus Standard Timing in the Treatment of Severe Lower Extremity Musculoskeletal Injuries | Johns Hopkins University | Not applicable | Not yet recruiting | Open Tibia Fracture, Open Dislocation of Ankle, Extremity Fracture Lower, Extremity Injuries Lower | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828613) |
| September 18, 2026 | NCT07827573 | A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on... | Hoffmann-La Roche | Phase 3 | Recruiting | Early Breast Cancer, Estrogen Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827573) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| Oregon Health and Science University | Portland | 193 |
| Oregon Health & Science University | Portland | 170 |
| Providence Portland Medical Center | Portland | 126 |
| Providence Saint Vincent Medical Center | Portland | 92 |
| Providence Newberg Medical Center | Newberg | 77 |
| Providence Willamette Falls Medical Center | Oregon City | 74 |
| Saint Alphonsus Cancer Care Center-Ontario | Ontario | 60 |
| Clackamas Radiation Oncology Center | Clackamas | 53 |
| Saint Charles Health System | Bend | 51 |
| OHSU Knight Cancer Institute | Portland | 46 |
| Bay Area Hospital | Coos Bay | 40 |
| Saint Charles Health System-Redmond | Redmond | 39 |
| Providence Cancer Institute Clackamas Clinic | Clackamas | 38 |
| Saint Alphonsus Cancer Care Center-Baker City | Baker City | 36 |
| Providence Hood River Memorial Hospital | Hood River | 29 |
| Providence St. Vincent Medical Center | Portland | 27 |
| VA Portland Health Care System, Portland, OR | Portland | 26 |
| Kaiser Permanente Northwest | Portland | 24 |
| Oregon Health & Science University (OHSU) | Portland | 22 |
| Oregon Health Sciences University | Portland | 20 |
| Legacy Good Samaritan Hospital and Medical Center | Portland | 18 |
| Legacy Emanuel Children's Hospital | Portland | 18 |
| Legacy Meridian Park Hospital | Tualatin | 16 |
| Legacy Mount Hood Medical Center | Gresham | 14 |
| Oregon Health & Sciences University | Portland | 13 |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 4 |
| Phase 1 | 71 |
| Phase 1/2 | 94 |
| Phase 2 | 200 |
| Phase 2/3 | 49 |
| Phase 3 | 355 |
| Phase 4 | 44 |
| Not applicable | 230 |
| Observational | 170 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 70 |
| Neoplasms | 48 |
| Breast Neoplasms | 45 |
| Prostatic Neoplasms | 42 |
| Ovarian Neoplasms | 34 |
| Lung Neoplasms | 33 |
| Neoplasm Metastasis | 33 |
| Endometrial Neoplasms | 31 |
| Leukemia, Myeloid, Acute | 30 |
| Colorectal Neoplasms | 29 |
| Heart Failure | 25 |
| Multiple Myeloma | 24 |
| Squamous Cell Carcinoma of Head and Neck | 21 |
| Pancreatic Neoplasms | 20 |
| Cardiovascular Diseases | 19 |
| Obesity | 19 |
| Melanoma | 17 |
| Recurrence | 17 |
| Stomach Neoplasms | 17 |
| Lymphoma, Non-Hodgkin | 16 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 16 |
| Urinary Bladder Neoplasms | 15 |
| Lymphoma, Large B-Cell, Diffuse | 15 |
| Carcinoma, Renal Cell | 14 |
| Triple Negative Breast Neoplasms | 14 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Oregon Health and Science University | 90 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 47 |
| National Cancer Institute (NCI) | 44 |
| OHSU Knight Cancer Institute | 40 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 28 |
| VA Office of Research and Development | 27 |
| SWOG Cancer Research Network | 23 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 21 |
| Children's Oncology Group | 21 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 20 |
| Alliance for Clinical Trials in Oncology | 20 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 18 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 18 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 17 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 16 |
| NRG Oncology | 13 |
| University of Oregon | 10 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 10 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 10 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 9 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 9 |
| ECOG-ACRIN Cancer Research Group | 9 |
| Jaeb Center for Health Research | 8 |
| Duke University | 7 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 7 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Oregon

- [B2B environmental companies in Oregon, United States](https://specstream.ai/data/businesses/b2b-environmental-companies/oregon-united-states)
- [Commercial real estate firms in Oregon, United States](https://specstream.ai/data/businesses/commercial-real-estate-firms/oregon-united-states)
- [Farm equipment suppliers in Oregon, United States](https://specstream.ai/data/businesses/farm-equipment-suppliers/oregon-united-states)
- [Internet service providers in Oregon, United States](https://specstream.ai/data/businesses/internet-service-providers/oregon-united-states)
- [Neurology practices in Oregon, United States](https://specstream.ai/data/businesses/neurology-practices/oregon-united-states)
- [Radiology practices in Oregon, United States](https://specstream.ai/data/businesses/radiology-practices/oregon-united-states)
